Evidence map›Paper›PMID 31896688›Full record

ArticleGenes & development2020

Linking cancer transcriptional addictions by CDK7 to YAP/TAZ.

Stefano Piccolo

Open access · diamondAbstract readComment
In one paragraph

Article in Genes & development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Genomics and Functional Genomics of Malignant Pleural Mesothelioma.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Stefano PiccoloDepartment of Molecular Medicine, University of Padua School of Medicine, 35121 Padua, Italy; IFOM, The FIRC Institute of Molecular Oncology, 35121 Padua, Italy piccolo@bio.unipd.it.
FIRC Institute of Molecular Oncology · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of CDK7 is a promising strategy for cancer therapy. CDK7 so far has been understood mainly in the context of Pol II-driven transcription. However, how are the roles of CDK7 in the "basal" transcriptional machinery reconciled with the function of CDK7 as inducer of specific transcriptional programs in tumor cells? In this issue of

Indexed as

NeoplasmsTranscription FactorsAdaptor Proteins, Signal TransducingHippo Signaling PathwayHumansOrgan SizePhosphoproteinsProtein Serine-Threonine KinasesAdaptor Proteins, Signal TransducingPhosphoproteinsProtein Serine-Threonine KinasesTranscription Factorscancerorgan sizeCDK3CRL4Cul4DCAF12HippoTazYapYki

Identifiers

PMID31896688
PMCPMC6938668
OpenAlexW2997899376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.